Body fluid biomarkers in multiple sclerosis

[1]  H. Zetterberg,et al.  Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis , 2014, Multiple sclerosis.

[2]  G. Giovannoni,et al.  Cerebrospinal fluid and urinary biomarkers in multiple sclerosis , 2013, Acta neurologica Scandinavica.

[3]  M. Pirinen,et al.  Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis , 2013, Nature Genetics.

[4]  F. Fazekas,et al.  Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis , 2013, Multiple sclerosis.

[5]  J. Hillert,et al.  Characterization of anti-natalizumab antibodies in multiple sclerosis patients , 2013, Multiple sclerosis.

[6]  P. Nichelli,et al.  Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with Clinically Isolated Syndrome , 2013, Journal of Neuroimmunology.

[7]  R. Lahesmaa,et al.  Genome-wide comparison of two RNA-stabilizing reagents for transcriptional profiling of peripheral blood. , 2013, Translational research : the journal of laboratory and clinical medicine.

[8]  P. Aspelin,et al.  Radiologically isolated syndrome – incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review , 2013, Multiple sclerosis.

[9]  A. Coles.  Alemtuzumab Treatment of Multiple Sclerosis , 2013, Seminars in Neurology.

[10]  R. Rudick,et al.  Predictors of long‐term outcome in multiple sclerosis patients treated with interferon beta , 2013, Annals of neurology.

[11]  L. Steinman,et al.  Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS , 2012, Neurology.

[12]  Brett Houser,et al.  Bio-Rad’s Bio-Plex® suspension array system, xMAP technology overview , 2012, Archives of physiology and biochemistry.

[13]  C. McCulloch,et al.  Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis , 2012, Annals of neurology.

[14]  A. Ponsonby,et al.  Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS , 2012, Neurology.

[15]  H. Alder,et al.  miRNA profiling for biomarker discovery in multiple sclerosis: From microarray to deep sequencing , 2012, Journal of Neuroimmunology.

[16]  Bernhard Hemmer,et al.  Potassium channel KIR4.1 as an immune target in multiple sclerosis. , 2012, The New England journal of medicine.

[17]  A. Großhennig,et al.  Personalized medicine using DNA biomarkers: a review , 2012, Human Genetics.

[18]  A. Wu,et al.  Cerebrospinal Fluid BAFF and APRIL Levels in Neuromyelitis Optica and Multiple Sclerosis Patients During Relapse , 2012, Journal of Clinical Immunology.

[19]  Meena Subramanyam,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.

[20]  Jeffrey A Cohen,et al.  Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects , 2012, The Lancet Neurology.

[21]  J. Ranjeva,et al.  Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual , 2012, Multiple sclerosis.

[22]  R. Lichtinghagen,et al.  Anticoagulants affect matrix metalloproteinase 9 levels in blood samples of stroke patients and healthy controls. , 2012, Clinical biochemistry.

[23]  David H. Miller,et al.  Clinically isolated syndromes , 2012, The Lancet Neurology.

[24]  H. Hartung,et al.  Vaccination against infection in patients with multiple sclerosis , 2012, Nature Reviews Neurology.

[25]  T. Waldmann,et al.  Intrathecal effects of daclizumab treatment of multiple sclerosis , 2011, Neurology.

[26]  M. Pirmohamed,et al.  Pharmacogenomics in neurology: Current state and future steps , 2011, Annals of neurology.

[27]  A. Sandrock,et al.  Anti‐John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY‐1 , 2011, Annals of neurology.

[28]  A. Winkelmann,et al.  Fingolimod treatment for multiple sclerosis Patients What Do We Do with Varicella? , 2011, Annals of neurology.

[29]  D. Szymkowski,et al.  Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. , 2011, Brain : a journal of neurology.

[30]  L. Kappos,et al.  Evaluation of soluble HLA-G as a biomarker for multiple sclerosis , 2011, Neurology.

[31]  Simon C. Potter,et al.  Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis , 2011, Nature.

[32]  A. Ascherio,et al.  Anti-Epstein–Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel , 2011, Multiple sclerosis.

[33]  J. Correale,et al.  Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis , 2011, Multiple sclerosis.

[34]  Daniela Pohl,et al.  Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study , 2011, The Lancet Neurology.

[35]  X. Montalban,et al.  Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: An ongoing story , 2011, Journal of Neuroimmunology.

[36]  P. Sørensen,et al.  Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab , 2011, Multiple sclerosis.

[37]  H. Vrenken,et al.  Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry , 2011, Multiple sclerosis.

[38]  M. Bassetti,et al.  Primary varicella zoster infection associated with fingolimod treatment , 2011, Neurology.

[39]  D. Galimberti,et al.  Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid , 2011, Multiple sclerosis.

[40]  T. Olsson,et al.  Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course , 2011, Multiple sclerosis.

[41]  M. Pinto-Medel,et al.  Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months , 2011, Multiple sclerosis.

[42]  Daniel J Sargent,et al.  Integrating biomarkers in clinical trials , 2011, Expert review of molecular diagnostics.

[43]  P. Nichelli,et al.  Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM , 2011, Multiple sclerosis.

[44]  L. Kappos,et al.  Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis , 2011, Neurology.

[45]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[46]  Yuhong Yang,et al.  Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? , 2011, Biochimica et biophysica acta.

[47]  T. Olsson,et al.  A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis , 2011, Multiple sclerosis.

[48]  P. Sørensen,et al.  Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis , 2011, Multiple sclerosis.

[49]  S. Hauser,et al.  Aggregation of multiple sclerosis genetic risk variants in multiple and single case families , 2011, Annals of neurology.

[50]  T. Olsson,et al.  Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab , 2011, Annals of neurology.

[51]  B. Sela,et al.  Free light chain monomers in the diagnosis of multiple sclerosis , 2010, Journal of Neuroimmunology.

[52]  D. Chan,et al.  The Road from Discovery to Clinical Diagnostics: Lessons Learned from the First FDA-Cleared In Vitro Diagnostic Multivariate Index Assay of Proteomic Biomarkers , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[53]  K. Simon,et al.  Anti‐JC virus antibodies: Implications for PML Risk Stratification , 2010, Annals of neurology.

[54]  T. Luider,et al.  Proteomics Comparison of Cerebrospinal Fluid of Relapsing Remitting and Primary Progressive Multiple Sclerosis , 2010, PloS one.

[55]  G. Giovannoni,et al.  Neural cell adhesion molecule — Description of a CSF ELISA method and evidence of reduced levels in selected neurological disorders , 2010, Journal of Neuroimmunology.

[56]  Bernhard Hemmer,et al.  Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis , 2010, The Lancet Neurology.

[57]  Max-Philipp Stenner,et al.  Upregulation of K2P5.1 potassium channels in multiple sclerosis , 2010, Annals of neurology.

[58]  G. Ingram,et al.  Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. , 2010, Brain : a journal of neurology.

[59]  T. Olsson,et al.  Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. , 2010, Journal of proteomics.

[60]  À. Rovira,et al.  Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. , 2010, Brain : a journal of neurology.

[61]  Xavier Montalban,et al.  Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta , 2010, The Lancet Neurology.

[62]  D. Clifford,et al.  Natalizumab-associated progressive multifocal leukoencephalopathy. , 2012 .

[63]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[64]  J. García,et al.  Brote de sarampión en Barcelona. Características clínicas y epidemiológicas , 2010 .

[65]  Christian Confavreux,et al.  Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion , 2010, Multiple sclerosis.

[66]  P. Sørensen,et al.  Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS , 2009, Neurology.

[67]  J. Fleming,et al.  A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking , 2009, Neurology.

[68]  X. Montalban,et al.  A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. , 2009, Brain : a journal of neurology.

[69]  E. Tolosa,et al.  Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. , 2009, Brain : a journal of neurology.

[70]  A. Ludolph,et al.  IgG Antibodies against Measles, Rubella, and Varicella Zoster Virus Predict Conversion to Multiple Sclerosis in Clinically Isolated Syndrome , 2009, PloS one.

[71]  C. Giachelli,et al.  The role of osteopontin in inflammatory processes , 2009, Journal of Cell Communication and Signaling.

[72]  E. Donadi,et al.  Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse , 2009, Neuroscience Letters.

[73]  F. Sellebjerg,et al.  Absence of MxA induction by interferon β in patients with MS reflects complete loss of bioactivity , 2009, Neurology.

[74]  Arcadi Navarro,et al.  Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. , 2009, Archives of neurology.

[75]  Ludwig Kappos,et al.  Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci , 2009, Nature Genetics.

[76]  Pablo Moscato,et al.  Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20 , 2009, Nature Genetics.

[77]  E. Urcelay,et al.  Glypican 5 is an interferon-beta response gene: a replication study , 2009, Multiple sclerosis.

[78]  X. Bossuyt.  Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. , 2009, Autoimmunity reviews.

[79]  F. Bouwman,et al.  Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis , 2009, Neurology.

[80]  T. Waldmann,et al.  Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. , 2009, Archives of neurology.

[81]  M. Racke,et al.  Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? , 2009, Expert review of neurotherapeutics.

[82]  Michael R. Johnson,et al.  Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. , 2009, Human molecular genetics.

[83]  J. Litzman,et al.  Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis , 2009, Multiple sclerosis.

[84]  C. Constantinescu,et al.  Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study , 2008, The Lancet Neurology.

[85]  Stephen L. Hauser,et al.  Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event , 2008, Proceedings of the National Academy of Sciences.

[86]  P. Stadler,et al.  HLA-DRB1∗0401 and HLA-DRB1∗0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis , 2008, The American Journal of Human Genetics.

[87]  T. Brücke,et al.  Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis , 2008, Journal of Neurology.

[88]  K. Selmaj,et al.  SOLUBLE NOGO-A IN CSF IS NOT A USEFUL BIOMARKER FOR MULTIPLE SCLEROSIS , 2008, Neurology.

[89]  Stephen Sawcer,et al.  The complex genetics of multiple sclerosis: pitfalls and prospects , 2008, Brain : a journal of neurology.

[90]  A. Rovira,et al.  Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? , 2008, Neurology.

[91]  Pablo Villoslada,et al.  Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. , 2008, Archives of neurology.

[92]  D. Miller,et al.  The incidence and significance of anti-natalizumab antibodies , 2007, Neurology.

[93]  B. Weinshenker,et al.  The spectrum of neuromyelitis optica , 2007, The Lancet Neurology.

[94]  J. Kukal,et al.  Antibodies against light neurofilaments in multiple sclerosis patients , 2007, Acta neurologica Scandinavica.

[95]  D. Gambi,et al.  Cleavage of cystatin C is not associated with multiple sclerosis , 2007, Annals of neurology.

[96]  Roland Martin,et al.  Genomics in multiple sclerosis—Current state and future directions , 2007, Journal of Neuroimmunology.

[97]  O. Kvalheim,et al.  Pre‐analytical influence on the low molecular weight cerebrospinal fluid proteome , 2007, Proteomics. Clinical applications.

[98]  Hans Lassmann,et al.  The Immunopathology of Multiple Sclerosis: An Overview , 2007, Brain pathology.

[99]  D. Goodin,et al.  Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: [RETIRED] , 2007, Neurology.

[100]  P. Vermersch,et al.  Immunosuppressive therapy is more effective than interferon in neuromyelitis optica , 2007, Multiple sclerosis.

[101]  Y. Matsumoto,et al.  Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination , 2007, Journal of the Neurological Sciences.

[102]  David H. Miller,et al.  Lack of association between antimyelin antibodies and progression to multiple sclerosis. , 2007, The New England journal of medicine.

[103]  Douglas B. Kell,et al.  Statistical strategies for avoiding false discoveries in metabolomics and related experiments , 2007, Metabolomics.

[104]  A. Ascherio,et al.  Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. , 2006, JAMA.

[105]  H. Link,et al.  Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness , 2006, Journal of Neuroimmunology.

[106]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[107]  M. Plebani.  Errors in clinical laboratories or errors in laboratory medicine? , 2006, Clinical chemistry and laboratory medicine.

[108]  E. Granieri,et al.  Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis , 2006, Multiple sclerosis.

[109]  A. Ascherio,et al.  Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. , 2006, Archives of neurology.

[110]  M. Sá,et al.  Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis , 2006, Multiple sclerosis.

[111]  B. Weinshenker,et al.  Revised diagnostic criteria for neuromyelitis optica , 2006, Neurology.

[112]  Maya Ram,et al.  Matrix Metalloproteinase-9 and Autoimmune Diseases , 2006, Journal of Clinical Immunology.

[113]  T. Waldmann,et al.  Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[114]  S. Kozek-Langenecker,et al.  The Effects of Test Temperature and Storage Temperature on Platelet Aggregation: A Whole Blood In Vitro Study , 2006, Anesthesia and analgesia.

[115]  H. Tumani,et al.  Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis , 2006, Multiple sclerosis.

[116]  Christian Confavreux,et al.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[117]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[118]  X. Montalban,et al.  Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients , 2006, Annals of neurology.

[119]  C. Weiller,et al.  Elevated levels of neural recognition molecule L1 in the cerebrospinal fluid of patients with Alzheimer disease and other dementia syndromes , 2006, Neurobiology of Aging.

[120]  C. Pozzilli,et al.  Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosis , 2005, European journal of neurology.

[121]  G. Cutter,et al.  MRI as a marker for disease heterogeneity in multiple sclerosis , 2005, Neurology.

[122]  C. V. Jensen,et al.  Acute axonal damage predicts clinical outcome in patients with multiple sclerosis , 2005, Multiple sclerosis.

[123]  E. Marchiori,et al.  Sample handling for mass spectrometric proteomic investigations of human sera. , 2005, Analytical chemistry.

[124]  F. Angelucci,et al.  Neurotrophic Factors and Clinical Recovery in Relapsing‐Remitting Multiple Sclerosis , 2005, Scandinavian journal of immunology.

[125]  J. Ioannidis.  Why Most Published Research Findings Are False , 2005, PLoS medicine.

[126]  D. Bernard,et al.  Quantification of Immunoglobulin Free Light Chains in CerebroSpinal Fluid by Nephelometry , 2005, Journal of Clinical Immunology.

[127]  Gavin Giovannoni,et al.  Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. , 2005, Archives of neurology.

[128]  X. Montalban,et al.  Plasma osteopontin levels in multiple sclerosis , 2005, Journal of Neuroimmunology.

[129]  J. Masjuán,et al.  Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. , 2005, The Journal of clinical investigation.

[130]  Ichiro Nakashima,et al.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.

[131]  N. Norgren,et al.  Neurofilament and glial fibrillary acidic protein in multiple sclerosis , 2004, Neurology.

[132]  F. Barkhof,et al.  CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis , 2004, Neurology.

[133]  C. Polman,et al.  Osteopontin levels and increased disease activity in relapsing–remitting multiple sclerosis patients , 2004, Journal of Neuroimmunology.

[134]  J. Dillner,et al.  An altered immune response to Epstein-Barr virus in multiple sclerosis , 2004, Neurology.

[135]  J. Archelos,et al.  Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG , 2004, Journal of Neurology.

[136]  Nader Rifai,et al.  Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. , 2003, Clinical chemistry.

[137]  S. Ozakbas,et al.  Nitric oxide as an activity marker in multiple sclerosis , 2003, Journal of Neurology.

[138]  B. Weinshenker,et al.  Neuromyelitis optica , 2003, Neurology.

[139]  M. Trojano,et al.  Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes , 2003, Journal of Neuroimmunology.

[140]  R. Lindberg,et al.  Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients , 2003, Neurology.

[141]  E. Waubant,et al.  IFNβ lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS , 2003, Neurology.

[142]  V. Gallai†,et al.  Brain-derived neurotrophic factor in patients with multiple sclerosis , 2002, Journal of Neuroimmunology.

[143]  C. Polman,et al.  Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. , 2002, Brain : a journal of neurology.

[144]  R. Eastell,et al.  Effect of feeding on bone turnover markers and its impact on biological variability of measurements. , 2002, Bone.

[145]  E. Silber,et al.  Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit , 2002, Neurology.

[146]  A. Massaro.  The role of NCAM in remyelination , 2002, Neurological Sciences.

[147]  D. Devos,et al.  Silver stained isoelectrophoresis of tears and cerebrospinal fluid in multiple sclerosis , 2001, Journal of Neurology.

[148]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[149]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[150]  C. Wolf,et al.  Science, medicine, and the future: Pharmacogenetics. , 2000, BMJ.

[151]  R. Miller,et al.  Increased urinary nitric oxide metabolites in patients with multiple sclerosis correlates with early and relapsing disease , 1999, Multiple sclerosis.

[152]  P C O'Brien,et al.  The clinical course of neuromyelitis optica (Devic’s syndrome) , 1999, Neurology.

[153]  T. Olsson,et al.  Increased intrathecal nitric oxide formation in multiple sclerosis; cerebrospinal fluid nitrite as activity marker , 1999, European journal of neurology.

[154]  D. Paty,et al.  TNF neutralization in MS , 1999, Neurology.

[155]  M. Reindl,et al.  Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies , 1999, Neurology.

[156]  P. Jongen,et al.  Myelin basic protein in CSF as indicator of disease activity in multiple sclerosis , 1998, Multiple sclerosis.

[157]  W. Tourtellotte,et al.  Acute optic neuritis: combined immunological markers and magnetic resonance imaging predict subsequent development of multiple sclerosis , 1998, Journal of the Neurological Sciences.

[158]  R Dybkaer,et al.  Vocabulary for use in measurement procedures and description of reference materials in laboratory medicine. , 1997, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[159]  S. Reingold,et al.  Defining the clinical course of multiple sclerosis , 1996, Neurology.

[160]  D. Paty,et al.  Correlation of clinical features and findings on cranial magnetic resonance imaging with urinary myelin basic protein‐like material in patients with multiple sclerosis , 1994, Annals of neurology.

[161]  F. Barkhof,et al.  A correlative triad of gadolinium‐DTPA MRI, EDSS, and CSF‐MBP in relapsing multiple sclerosis patients treated with high‐dose intravenous methylprednisolone , 1992, Neurology.

[162]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[163]  J. Seyer,et al.  Immunoreactive myelin basic protein in the cerebrospinal fluid in neurological disorders , 1980, Transactions of the American Neurological Association.

[164]  U. Zettl,et al.  Immunization in the adult immunocompromised host. , 2012, Autoimmunity reviews.

[165]  Angel Alberich-Bayarri,et al.  Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes , 2011, Neuroradiology.

[166]  Wei Ding,et al.  Current Omics Technologies in Biomarker Discovery , 2011, Handbook of Research on Computational and Systems Biology.

[167]  L. Rosengren,et al.  Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis , 2010, Journal of Neurology.

[168]  Jia Newcombe,et al.  Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. , 2008, The American journal of pathology.

[169]  M. Comabella,et al.  GENOMICS IN MULTIPLE SCLEROSISCURRENT STATE AND FUTURE DIRECTIONS , 2007 .

[170]  D. Allison,et al.  Microarray data analysis: from disarray to consolidation and consensus , 2006, Nature Reviews Genetics.

[171]  Wolfgang Schreiber,et al.  Nocturnal plasma levels of cytokines in healthy men , 2005, European Archives of Psychiatry and Clinical Neuroscience.